Medtronic Continues To Run (RNA) Interference With Alnylam
This article was originally published in The Pink Sheet Daily
Executive Summary
Device firm is upping its investment in biotech drug delivery by expanding its collaboration with Alnylam for development of an RNA-based treatment for Huntington’s disease.
You may also be interested in...
Merck Passes Huntington’s RNAi Program To Targeted Genetics
Sirna division’s early-stage targets are of lesser interest to the pharma firm, analyst tells “The Pink Sheet” DAILY.
Merck Passes Huntington’s RNAi Program To Targeted Genetics
Sirna division’s early-stage targets are of lesser interest to the pharma firm, analyst tells “The Pink Sheet” DAILY.
Alnylam’s Next Move: Testing RSV Candidate In Naturally-Infected Adults, Pediatric Patients
RNAi-focused biotech also says it anticipates IND filings this year for hypercholesterolemia and liver cancer candidates.